U.S. Markets closed

Northwest Biotherapeutics, Inc. (NWBO)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.219+0.004 (+1.860%)
At close: 3:52PM EDT
People also watch
IMUCGALECLDXIDRATHLD
  • A
    Andrew
    Andrew
    Something is definitely brewing-multiple large orders being placed driving this thing higher-and-higher. Volume also up big and no apparent efforts to beat it back down (like an aggressive day-trader might)
  • J
    Joe
    Joe
    I would expect a short squeeze at around 30.5c if this trend continues. I can see it close to $1 per share before the release of data this weekend or next week. Then it will rocket up or down. Companies with much less interesting preliminary data do much better than NWBO. If (big if) data is positive it will be a game changer in cancer management and I have to thank Adam F & Co for giving me the opportunity to buy the shares so cheaply.
  • K
    Keith&Katrina
    Keith&Katrina
    For a mathematically sound judgement on probability of success of phase 3 please review alphapuppy's posts on IHUB. One you will be educated and two any doubts you may have will evaporate. As for the basher's please go ahead and post your statistical evidence that refutes his findings. I bet there is not a single basher on this board that will provide statistical evidence of failure.
  • M
    MolecularMedicine
    MolecularMedicine
    data lock a'comin'
    brace yourselves
    watch volume
  • U
    UDIPI
    UDIPI
    Recently, many competing immunotherapies have failed, sadly. DNDN's Provenge vaccine is the only one approved by the FDA so far, whose underlying science is closest to that of DCVax-L. DCVax-L is the only one still standing tall even now, upping its value higher and higher as it approaches its data lock, which appears to be like a mirage.
  • W
    William
    William
    approval will change the landscape for cancer vaccines and bio tech investors..
  • D
    Ducks of Oregon
    Ducks of Oregon
    Another round of financing to be announced.
  • W
    William
    William
    invested here only for phase 3 outcome..nothing else really matters
  • b
    brian
    brian
    my Crystal ball says .31 cents by end of day
  • D
    Dennis
    Dennis
    1.5 Billion market cap would make what share price?
  • C
    Clarence
    Clarence
    WHY DOES FEUERSTEIN feel humiliated by Washington Post's, Pearstein's attack on him/Feuerstein
    and was it the beginning of the end for his tenure at 'the street?'
    WP reporter writes a "hit piece" on (gasp!) Mr. Feuerstein
    Sep. 30, 2014 11:00 AM ET|By: Douglas W. House, SA News Editor

    TheStreet's Editor-In-Chief Janet Guyon writes an extensive rebuttal to an article published on September 27 by the Washington Post's Steven Pearlstein where he accuses Adam Feuerstein of being in bed with short sellers regarding Northwest Biotherapeutics (NWBO -1.9%). In short, he accuses AF of securities fraud.

    TheStreet, unsurprisingly, takes exception to the piece saying Mr. Feuerstein does not own shares in NWBO, is not in cahoots with any hedge funds and supports his articles with facts. Ms. Guyon requests a retraction.

    Many observers will undoubtedly find the situation humorous considering AF's confrontational style. Mr. Pearlstein, however, questions his integrity which is out of bounds without the facts to back it up.
  • C
    Clarence
    Clarence
    by starting with the most difficult to treat beain cancers.....this vould rake in Billions is soft tissue and other cancers,,,,,valuation could be billions coming soon?
  • M
    MLange
    MLange

    Expect even more pullback today after Feuerstein and this from yesterday. Carroll makes it a point to specifically list NWBO. The only commonality between the companies is the word "vaccine" completely different processes and drug makeup. Classic hit article taking out 2 companies in 1 swoop.

    https://endpts.com/kerrisdale-2-0-this-week-bavarian-nordic-cancer-vaccine-is-a-bust-in-phiii/

    Kerrisdale 2-0 this week: Bavarian Nordic's cancer vaccine is a bust in PhIII
    Another cancer vaccine has bitten the dust. Six long years after starting their Phase III trial for the prostate cancer vaccine Prostvac, an independent monitoring committee says it’s time to simply scrap Bavarian Nordic’s {$BAVA.CO} study after conc
    endpts.com
  • M
    MolecularMedicine
    MolecularMedicine
    getting the popcorn ready, now.
  • D
    Dennis
    Dennis
    My opinion is we get a 5-7/1 RS with news...any thoughts from serious people. That would leave 86 or 61M... not a big fan of RS but with great news it's binary and won't make any difference.
  • A
    Anonymous
    Anonymous
    Linda DILUTED NWBO, so limited upside, with 300 million shares outstanding!
  • D
    Dan
    Dan
    We need a hell of a lot more volume to anticipate the next move in this stock.
  • U
    UDIPI
    UDIPI
    The science behind DCVax-L and Prostvac vaccines are totally different. DCVax-L is a personalized vaccine, which is customized to each patient, with activation against several hundreds of patient's own tumor antigens. Whereas, Prostvac uses "off the shelf" two poxviruses in a prime boost vaccine regimen for all the patients. Prostvac vaccine is not customized to each patient- that is, "one size fits all" type of vaccine with only 2 poxviruses to fight against the tumor, which could be mutating to escape from the attack.
  • W
    William
    William
    hard to imagine who is selling now..got to be naked shorting..
  • M
    MichaelK
    MichaelK
    I watched the video on the site and heard the description of the biological process the vaccine was intended to promote. It was a real stretch and very different from DCVax. To compare the two was wrong. But why would that stop AF? Provenge is the closest treatment that has ever been created that is built in similar manner; it was approved by the FDA. I expect DCVax to have as good a chance or better of getting approval. Carrol and AF are buddies and probably collaborated. It would not be the first time.